University of Maryland School of Medicine researchers engineered a type of CAR T-cell therapy that, in preclinical studies, selectively attacked cancer cells while sparing healthy cells, potentially reducing the likelihood of toxic side effects from this innovative cancer treatment.
Merck and Moderna have initiated a phase III randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma.
A study led by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.
Investigators at the Icahn School of Medicine at Mount Sinai have designed a RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.
The American Society of Clinical Oncology has published guidelines outlining the need to assess and manage vulnerabilities in patients aged 65 and older prior to prescribing chemotherapy, targeted therapy and/or immunotherapy.
The phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda (pembrolizumab) in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) met one of its primary endpoints of progression-free survival as treatment for newly diagnosed patients with high-risk locally advanced cervical cancer.
A new study by investigators from Brigham and Women’s Hospital in a preclinical model demonstrates the potential for restoring fertility when the ovaries have stopped working.
Research directed by Johns Hopkins showed that for patients with operable pancreatic cancers, a three-pronged combination immunotherapy treatment—consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment—is safe, increases the amount of cancer-killing immune system T cells in the tumors, and appears effective when given two weeks prior to cancer-removal surgery. A description of the work was published in Nature Communications.
The dose escalation portion of the ongoing ANTLER phase I trial showed positive long-term follow-up clinical data for CB-010, an allogeneic anti-CD19 CAR-T cell therapy, in the treatment of relapsed or refractory B cell non-Hodgkin lymphoma.
Cedars-Sinai Cancer investigators found that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
